Cover Image
Market Research Report

Geriatric Medicines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published by Transparency Market Research Product code 626791
Published Content info 185 Pages
Delivery time: 1-2 business days
Price
Back to Top
Geriatric Medicines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Published: November 30, 2018 Content info: 185 Pages
Description

Global Geriatric Medicines Market: Overview

This report on the global geriatric medicines market analyzes the current and future prospects of the market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market value in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global geriatric medicines market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining expansion of the market and future opportunities has been provided in the market overview section. The report also provides insights into the key trends of the geriatric medicines market. The report includes market attractiveness analysis of the major geographic regions that provides a thorough analysis of the overall competitive scenario in the global geriatric medicines market.

Market value in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global geriatric medicines market for each segment is also reflected. Additionally, market-related factors such as growing geriatric population, favorable government policies for elderly and developing healthcare infrastructure in emerging countries and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Geriatric Medicines Market: Key Segments

The global geriatric medicines market has been segmented based on therapeutic category, condition, distribution channel, and region. In terms of therapeutic category, the geriatric medicine market has been divided into analgesic, antihypertensive, statins, antidiabetic, proton pump inhibitor, anticoagulant, antipsychotic & antidepressant, and others. In terms of condition, the market has been segregated into cardiovascular, arthritis, neurological, cancer, osteoporosis, respiratory, and others. In terms of distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Global Geriatric Medicines Market: Regional Outlook

In terms of region, the global geriatric medicines market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented into major countries in each of the regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia & New Zealand, Japan, India, Brazil, GCC, South Africa, and Mexico.

Companies Mentioned in Report

The report also profiles major players in the geriatric medicines market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Abbott Laboratories, and Boehringer Ingelheim GmbH.

The global geriatric medicines market has been segmented as follows:

  • Global Geriatric Medicines Market, by Therapeutic Category
  • Analgesic
  • Antihypertensive
  • Statins
  • Antidiabetic
  • Proton Pump Inhibitor
  • Anticoagulant
  • Antipsychotic and Antidepressant
  • Others
  • Global Geriatric Medicines Market, by Condition
  • Cardiovascular
  • Arthritis
  • Diabetes
  • Neurological
  • Cancer
  • Osteoporosis
  • Respiratory
  • Others
  • Global Geriatric Medicines Market, by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Geriatric Medicines Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • Australia & New Zealand
  • Japan
  • China
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa
Table of Contents

Table of Contents

Section 1 Preface

  • 1.1 Report Scope and Market Segmentation
  • 1.2 Research Highlights

Section 2 Assumptions and Research Methodology

  • 2.1 Assumptions
  • 2.2 Research Methodology

Section 3 Executive Summary

  • 3.1 Global Geriatric Medicines Market Snapshot
  • 3.2 Global Geriatric Medicines Market Share Analysis, by Region, 2017

Section 4 Market Overview

  • 4.1 Global Geriatric Medicines Market Taxonomy
  • 4.2 Global Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • 4.3 Global Geriatric Medicines Market: Market Outlook
  • 4.4 Key Industry Events

Section 5 Market Dynamics

  • 5.1 Drivers and Restraints Snapshot Analysis
  • 5.2 Drivers
    • 5.2.1 Increase in global geriatric population
    • 5.2.2 Rise in chronic diseases (stroke, respiratory, and arthritis)
    • 5.2.3 Increase in government support for elderly
    • 5.2.4 Technological advancements for medication assistance
  • 5.3 Restraints
    • 5.3.1 Significant shortfall of geriatricians in the world
    • 5.3.2 High chances of adverse drug reaction in elderly
    • 5.3.3 Lack of patient participation in clinical trials

Section 6 Geriatric Medicines Market Analysis, by Therapeutic Category

  • 6.1 Key Findings
  • 6.2 Introduction
  • 6.3 Global Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 6.4 Global Geriatric Medicines Market Forecast, by Therapeutic Category
  • 6.5 Global Geriatric Medicines Market Analysis, by Therapeutic Category
    • 6.5.1 Analgesic
    • 6.5.2 Antihypertensive
    • 6.5.3 Statins
    • 6.5.4 Antidiabetic
    • 6.5.5 Proton Pump Inhibitor
    • 6.5.6 Anticoagulant
    • 6.5.7 Antipsychotic and Antidepressant
    • 6.5.8 Others

Section 7 Global Geriatric Medicines Market Analysis, by Condition

  • 7.1 Key Findings
  • 7.2 Introduction
  • 7.3 Global Geriatric Medicines Market Value Share Analysis, by Condition
  • 7.4 Global Geriatric Medicines Market Forecast, by Condition
  • 7.5 Global Geriatric Medicines Market Analysis, by Condition
    • 7.5.1 Cardiovascular
    • 7.5.2 Arthritis
    • 7.5.3 Diabetes
    • 7.5.4 Neurological
    • 7.5.5 Cancer
    • 7.5.6 Osteoporosis
    • 7.5.7 Respiratory
    • 7.5.8 Others

Section 8 Global Geriatric Medicines Market Analysis, by Distribution Channel

  • 8.1 Key Findings
  • 8.2 Introduction
  • 8.3 Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 8.4 Global Geriatric Medicines Market Forecast, by Distribution Channel
  • 8.5 Global Geriatric Medicines Market Analysis, by Distribution Channel
    • 8.5.1 Hospital Pharmacies
    • 8.5.2 Retail Pharmacies
    • 8.5.3 Online Pharmacies

Section 9 Global Geriatric Medicines Market Analysis, by Region

  • 9.1 Global Geriatric Medicines Market Value Share Analysis, by Region
  • 9.2 Global Geriatric Medicines Market Forecast, by Region

Section 10 North America Geriatric Medicines Market Analysis, by Region

  • 10.1 Market Overview
  • 10.2 North America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country
  • 10.3 North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 10.4 North America Geriatric Medicines Market Forecast, by Therapeutic Category
  • 10.5 North America Geriatric Medicines Market Value Share Analysis, by Condition
  • 10.6 North America Geriatric Medicines Market Forecast, by Condition
  • 10.7 North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 10.8 North America Geriatric Medicines Market Forecast, by Distribution Channel
  • 10.9 North America Geriatric Medicines Market Value Share Analysis, by Country
  • 10.10 North America Geriatric Medicines Market Forecast, by Country
    • 10.10.1 U.S.
    • 10.10.2 Canada

Section 11 Europe Geriatric Medicines Market Analysis, by Region

  • 11.1 Market Overview
  • 11.2 Europe Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 11.3 Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 11.4 Europe Geriatric Medicines Market Forecast, by Therapeutic Category
  • 11.5 Europe Geriatric Medicines Market Value Share Analysis, by Condition
  • 11.6 Europe Geriatric Medicines Market Forecast, by Condition
  • 11.7 Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 11.8 Europe Geriatric Medicines Market Forecast, by Distribution Channel
  • 11.9 Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
  • 11.10 Europe Geriatric Medicines Market Forecast, by Country/Sub-region
    • 11.10.1 Germany
    • 11.10.2 U.K.
    • 11.10.3 France
    • 11.10.4 Spain
    • 11.10.5 Italy
    • 11.10.6 Rest of Europe

Section 12 Asia Pacific Geriatric Medicines Market Analysis, by Region

  • 12.1 Market Overview
  • 12.2 Asia Pacific Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 12.3 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 12.4 Asia Pacific Geriatric Medicines Market Forecast, by Therapeutic Category
  • 12.5 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition
  • 12.6 Asia Pacific Geriatric Medicines Market Forecast, by Condition
  • 12.7 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 12.8 Asia Pacific Geriatric Medicines Market Forecast, by Distribution Channel
  • 12.9 Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
  • 12.10 Asia Pacific Geriatric Medicines Market Forecast, by Country/Sub-region
    • 12.10.1 China
    • 12.10.2 Japan
    • 12.10.3 India
    • 12.10.4 Australia & New Zealand
    • 12.10.5 Rest of APAC

Section 13 Latin America Geriatric Medicines Market Analysis, by Region

  • 13.1 Market Overview
  • 13.2 Latin America Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 13.3 Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 13.4 Latin America Geriatric Medicines Market Forecast, by Therapeutic Category
  • 13.5 Latin America Geriatric Medicines Market Value Share Analysis, by Condition
  • 13.6 Latin America Geriatric Medicines Market Forecast, by Condition
  • 13.7 Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 13.8 Latin America Geriatric Medicines Market Forecast, by Distribution Channel
  • 13.9 Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
  • 13.10 Latin America Geriatric Medicines Market Forecast, by Country/Sub-region
    • 13.10.1 Brazil
    • 13.10.2 Mexico
    • 13.10.3 Rest of LATAM

Section 14 Middle East & Africa Geriatric Medicines Market Analysis, by Region

  • 14.1 Market Overview
  • 14.2 Middle East & Africa Geriatric Medicines Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 14.3 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Therapeutic Category
  • 14.4 Middle East & Africa Geriatric Medicines Market Forecast, by Therapeutic Category
  • 14.5 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Condition
  • 14.6 Middle East & Africa Geriatric Medicines Market Forecast, by Condition
  • 14.7 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Distribution Channel
  • 14.8 Middle East & Africa Geriatric Medicines Market Forecast, by Distribution Channel
  • 14.9 Middle East & Africa Geriatric Medicines Market Value Share Analysis, by Country/Sub-region
  • 14.10 Middle East & Africa Geriatric Medicines Market Forecast, by Country/Sub-region
    • 14.10.1 GCC
    • 14.10.2 South Africa
    • 14.10.3 Rest of MEA

Section 15 Company Profiles

    • 15.2.1 Pfizer, Inc.
      • 15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.1.2 Financial Overview
      • 15.2.1.3 Product Portfolio
      • 15.2.1.4 SWOT Analysis
      • 15.2.1.5 Strategic Overview
    • 15.2.2 Merck & Co., Inc.
      • 15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.2.2 Financial Overview
      • 15.2.2.3 Product Portfolio
      • 15.2.2.4 SWOT Analysis
      • 15.2.2.5 Strategic Overview
    • 15.2.3 AstraZeneca
      • 15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.3.2 Financial Overview
      • 15.2.3.3 Product Portfolio
      • 15.2.3.4 SWOT Analysis
      • 15.2.3.5 Strategic Overview
    • 15.2.4 Bristol-Myers Squibb Company
      • 15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.4.2 Financial Overview
      • 15.2.4.3 Product Portfolio
      • 15.2.4.4 SWOT Analysis
      • 15.2.4.5 Strategic Overview
    • 15.2.5 Novartis AG
      • 15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.5.2 Financial Overview
      • 15.2.5.3 Product Portfolio
      • 15.2.5.4 SWOT Analysis
      • 15.2.5.5 Strategic Overview
    • 15.2.6 Sanofi S.A.
      • 15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.6.2 Financial Overview
      • 15.2.6.3 Product Portfolio
      • 15.2.6.4 SWOT Analysis
      • 15.2.6.5 Strategic Overview
    • 15.2.7 GlaxoSmithKline plc
      • 15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.7.2 Financial Overview
      • 15.2.7.3 Product Portfolio
      • 15.2.7.4 SWOT Analysis
      • 15.2.7.5 Strategic Overview
    • 15.2.8 Eli Lilly and Company
      • 15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.8.2 Financial Overview
      • 15.2.8.3 Product Portfolio
      • 15.2.8.4 SWOT Analysis
      • 15.2.8.5 Strategic Overview
    • 15.2.9 Abbott Laboratories
      • 15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.9.2 Financial Overview
      • 15.2.9.3 Product Portfolio
      • 15.2.9.4 SWOT Analysis
      • 15.2.9.5 Strategic Overview
    • 15.2.10 Boehringer Ingelheim GmbH
      • 15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.10.2 Financial Overview
      • 15.2.10.3 Product Portfolio
      • 15.2.10.4 SWOT Analysis
      • 15.2.10.5 Strategic Overview

List of Tables

  • Table 01: Major Causes of Death for Persons Aged 65 or Over, 2014 (Standardized Death Rates per 100,000 Inhabitants)
  • Table 02: Healthcare Overview (2016 or latest available)
  • Table 03: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2016-2026
  • Table 04: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2016-2026
  • Table 05: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 06: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 07: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018-2026
  • Table 08: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018-2026
  • Table 09: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 10: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 11: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018-2026
  • Table 12: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018-2026
  • Table 13: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 14: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 15: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018-2026
  • Table 16: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018-2026
  • Table 17: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 18: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 19: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018-2026
  • Table 20: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018-2026
  • Table 21: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 22: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 23: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018-2026
  • Table 24: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018-2026
  • Table 25: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 26: Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026

List of Figures

  • Figure 01: Global Geriatric Medicines Market Snapshot
  • Figure 02: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016-2026
  • Figure 03: Global Geriatric Medicines Market Value Share by Therapeutic Category (2017)
  • Figure 04: Global Geriatric Medicines Market Value Share by Condition (2017)
  • Figure 05: Global Geriatric Medicines Market Value Share by Distribution Channel (2017)
  • Figure 06: Global Geriatric Medicines Market Value Share by Region (2017)
  • Figure 07: Global Geriatric Medicines Market Value Share, by Therapeutic Category, 2017 and 2026
  • Figure 08: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Analgesics
  • Figure 09: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Antihypertensive
  • Figure 10: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Statins
  • Figure 11: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Antidiabetic
  • Figure 12: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Proton Pump Inhibitor
  • Figure 13: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Anticoagulant
  • Figure 14: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Antipsychotic and Antidepressant
  • Figure 15: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Others
  • Figure 16: Global Geriatric Medicines Market Value Share, by Condition, 2017 and 2026
  • Figure 17: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Cardiovascular
  • Figure 18: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Arthritis
  • Figure 19: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Diabetes
  • Figure 20: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Neurological
  • Figure 21: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Cancer
  • Figure 22: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Osteoporosis
  • Figure 23: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Antipsychotic and Antidepressant
  • Figure 24: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026, by Others
  • Figure 25: Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 26: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016-2026
  • Figure 27: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016-2026
  • Figure 28: Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016-2026
  • Figure 29: Global Geriatric Medicines Market Value Share, by Region, 2017 and 2026
  • Figure 30: North America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 31: North America Geriatric Medicines Market Attractiveness Analysis, by Country
  • Figure 32: North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 33: North America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 34: North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 35: North America Geriatric Medicines Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 36: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 37: Europe Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 38: Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 39: Europe Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 40: Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 41: Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 42: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 43: Asia Pacific Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 44: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 45: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 46: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 47: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 48: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 49: Latin America Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 50: Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 51: Latin America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 52: Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 53: Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 54: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 55: Middle East & Africa (MEA) Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 56: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 57: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 58: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 59: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 60: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 61: Pfizer, Inc. R&D Intensity (%) - Company Level or Segment Level, 2015-2017
  • Figure 62: Pfizer, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 63: Merck & Co., Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 64: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014-2017
  • Figure 65: Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
  • Figure 66: AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2017
  • Figure 68: AstraZeneca Marketing & Sales and R&D Expenses, 2015-2017
  • Figure 69: Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 70: Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2015-2017
  • Figure 71: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2017
  • Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 73: Novartis AG Marketing & Sales and R&D Expenses, 2016-2017
  • Figure 74: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
  • Figure 75: Novartis AG Breakdown of Net Sales, by Region, 2017
  • Figure 76: Sanofi S.A. Breakdown of Net Sales, by Region, 2017
  • Figure 77: Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 78: Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2017
  • Figure 79: Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2015-2017
  • Figure 80: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 81: GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2015-2017
  • Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2017
  • Figure 83: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2017
  • Figure 84: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 85: Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2015-2017
  • Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
  • Figure 87: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 88: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2017
  • Figure 89: Abbott Laboratories, Breakdown of Net Sales, by Region 2017
  • Figure 90: Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 91: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2017
  • Figure 92: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2017
  • Figure 93: Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2014-2017
Back to Top